Examination of stratification of subjects based on SARS-CoV-2 S-IgG antibody levels before and after vaccination with the new corona vaccine using the compact immunoassay device IA-100

Not Applicable

Recruiting

• Conditions: Confirmation of antibody titers before and after vaccination with the new coronavirus; COVID-19 Antibody Testing; D000087124

• Registration Number: JPRN-jRCT1032230148
• Lead Sponsor: Haruo Ozaki

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2023-06-16
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 160

Inclusion Criteria

Persons who are able to obtain written consent from the person himself/herself or a representative (including family members, relatives, and adult guardians) and who do not meet all of the following gratitude criteria

Exclusion Criteria

A facility resident who was judged by the attending physician to be inappropriate for this study.
Institutional residents under the age of 65.
Institutional residents with a history of bleeding disorders.
Institutional residents with a history of vagal reflexes.
Facility residents who do not wish to be vaccinated against COVID-19 during their stay in the facility

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Whether subjects can be stratified based on the amount of SARS-CoV-2 S-IgG antibodies before and after COVID-19 vaccination

Secondary Outcome Measures

Name	Time	Method
Examination of whether there is an association between stratified subject groups and vaccine type, whether they were infected with the new coronavirus before the booster vaccination, age, gender, and whether they were infected after the booster vaccination.